Shopping Cart
- Remove All
Your shopping cart is currently empty
LLY-507
🥰Excellent
Catalog No. T6879Cas No. 1793053-37-8
Alias LLY507, LLY 507
LLY-507 is an effective, cell-active, and specific inhibitor of protein-lysine Methyltransferase SMYD2.
LLY-507
🥰Excellent
Purity: 99.93%
Catalog No. T6879Alias LLY507, LLY 507Cas No. 1793053-37-8
LLY-507 is an effective, cell-active, and specific inhibitor of protein-lysine Methyltransferase SMYD2.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $37 | In Stock | |
| 2 mg | $50 | In Stock | |
| 5 mg | $77 | In Stock | |
| 10 mg | $140 | In Stock | |
| 25 mg | $321 | In Stock | |
| 50 mg | $581 | In Stock | |
| 100 mg | $829 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $112 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "LLY-507"
MAK-683 hydrochloride
T96812170606-94-5In house
MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.
- $195
Size
QTY
EPZ015666
GSK3235025
T60761616391-65-1
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity.
- $42
Size
QTY
MRTX-1719
T402542630904-45-7
MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.
- $398
Size
QTY
Tazemetostat
Cited
EPZ6438, E-7438
T17881403254-99-8
Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.
- $59
Size
QTY
CitedPiribedil
Trivastan, Trivastal, EU-4200, ET-495
T32783605-01-4
Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease.
- $52
Size
QTY
iso-Azalansta
Iso-RS-21607（Iso-143393-27-5）, Iso-RS-21607, Iso-Azalansta
T25127L143393-29-7
(2R,4S)-Azalanstat (Iso-Azalansta) is a selective heme oxygenase (HO) inhibitor that is used in the study of cardiovascular disease.
- $195
Size
QTY
MAK683
T152011951408-58-4In house
MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).
- $48
Size
QTY
XY1
T71571624117-53-8
XY1 is a close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), intended as a negative control for SGC707 in studies involving PRMT3 action.
- $31
Size
QTY
ORIC-944
ORIC944
T870732369769-29-7
ORIC-944 is an orally available and selective variant of PRC2 with anticancer activity for prostate cancer research.
- Inquiry Price
Size
QTY
AMI-1 free acid
T22239134-47-4
AMI-1 free acid is a potent, cell-permeable, and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with inhibitory concentration 50 (IC50) values of 8.8 μM for human PRMT1 and 3.0 μM for yeast-Hmt1p. It achieves its PRMTs inhibitory activity by obstructing peptide-substrate binding [1].
- $40
Size
QTY
MS37452
T21767423748-02-1
MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).
- $47
Size
QTY
BIX-01294 trihydrochloride Cited
BIX 01294
T19591392399-03-9
BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase.In a cell-free assay, the IC50=2.7 μM for G9a histone methyltransferase.
- $37
Size
QTY
CitedSelect Batch
Purity:99.93%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | LLY-507 is an effective, cell-active, and specific inhibitor of protein-lysine Methyltransferase SMYD2. |
| Targets&IC50 | SMYD2:15 nM. |
| In vitro | LLY-507 effectively inhibits the ability of SMYD2 to methylate p53 peptide (IC50<15 nM). LLY-507 is able to potently inhibit the methylation of the H4 peptide by the SMYD2 enzyme (IC50: 31 nM). It has 100-fold selectivity for SMYD2 than 24 other protein or DNA methyltransferases including related family members SMYD3 and SUVH420H1/SUV420H2. LLY-507 inactive (>20 μM) against three cytochrome P450 enzymes, 14 nuclear hormone receptors, 35 G protein-coupled receptors, and 454 kinases. LLY-507 dose-dependently inhibits the proliferation of several liver, esophageal, and breast cancer cell lines. |
| Cell Research | To examine the methylation status of p53 in HEK293 cells treated with LLY-507 by Western blotting, 2 × 105 cells are seeded in 6-well plates in triplicate and co-transfected with FLAG-tagged p53 and FLAG-tagged SMYD2 using Lipofectamine? 2000. The day after transfection, cells are treated with 0-2.5 μM LLY-507 for 28 h, then collected, and lysed in RIPA buffer. Cell lysates are subject to 10% SDS-PAGE and transferred to a PVDF membrane. |
| Alias | LLY507, LLY 507 |
| Molecular Weight | 574.76 |
| Formula | C36H42N6O |
| Cas No. | 1793053-37-8 |
| Smiles | Cc1cn(CCN2CCN(CC2)c2ccccc2-c2cc(cc(c2)C(=O)NCCCN2CCCC2)C#N)c2ccccc12 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 93 mg/mL (161.8 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 21 mg/mL (36.5 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy LLY-507 | purchase LLY-507 | LLY-507 cost | order LLY-507 | LLY-507 chemical structure | LLY-507 in vitro | LLY-507 formula | LLY-507 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.